ReviewClinics in chest medicine2019
Treatment of Drug-Resistant Tuberculosis.
Review in Clinics in chest medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Association of vitamin D receptor genetic variants with therapeutic response in multidrug-resistant pulmonary tuberculosis: a systematic review.Frontiers in cellular and infection microbiology · 2026Pooled it
- Pooled it
- Article
- Inflammasome activation dictates the efficacy of antimycobacterial activity of frontline TB drugs.PLoS pathogens · 2026Article
- Comparative evaluation of sputum microscopy and Xpert MTB/RIF assay for tuberculosis detection and rifampicin resistance surveillance in Biratnagar, Nepal.Microbiology spectrum · 2026Article
- Adjunctive Multicomponent Crystals of Two Anti-Tubercular Drugs with Pyridoxine.Pharmaceutics · 2026Article
- Diagnosis and Therapeutic Challenges of Drug-Resistant Tuberculosis Infection After Kidney Transplantation: A Rare Case Report.Infection and drug resistance · 2026Article
- Distinguishing tuberculosis from malignancy when multisystem involvement occurs: a case description.Quantitative imaging in medicine and surgery · 2026Article
- Development of machine learning models to identify potentially active compounds against tuberculosis.Scientific reports · 2025Article
- Divergent transcriptional regulation of redox-homeostasis and permeability modulate rifampicin tolerance and sensitivity in Mycobacterium tuberculosis.Nature communications · 2025Article
- Accuracy of Machine Learning in Identifying Drug Resistance in Tuberculosis: A Systematic Review and Meta-Analysis.Health science reports · 2025Review
- Trends in Antituberculosis Drug Resistance and Associated Factors: A 31-Year Observational Study at a Tertiary Hospital in Barcelona.Antibiotics (Basel, Switzerland) · 2025Article
- Disrupting tuberculosis pathogenesis by targeting DprE1 in cell wall biosynthesis: a structural dynamics perspective.Journal of computer-aided molecular design · 2025Article
- Nutritional Deficiencies and Management in Tuberculosis: Pharmacotherapeutic and Clinical Implications.Nutrients · 2025Review
- Head and Neck Tuberculosis: A Rare Diagnosis and the Role of Surgical Biopsy and Histopathological Evaluation in Extrapulmonary Disease.Pathogens (Basel, Switzerland) · 2025Article
- Comparative evaluation of five β-Lactamase inhibitors in combination with β-Lactams against multidrug-resistant Mycobacterium tuberculosis in vitro.BMC infectious diseases · 2025Article
- Demixer: a probabilistic generative model to delineate different strains of a microbial species in a mixed infection sample.Bioinformatics (Oxford, England) · 2025Article
- Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Prevalence and Genetic Analysis of Isoniazid-Resistant Tuberculosis in Eastern Uttar Pradesh, India.Cureus · 2025Article
- Efficacy and safety data on pretomanid for drug-resistant TB.IJTLD open · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
The treatment of drug-resistant tuberculosis (TB) is complicated and has evolved significantly in the past decade with the advent of rapid molecular tests and updated evidence-based guidelines of the World Health Organization and other organizations. The latest recommendations incorporate the use of new drugs and regimens that maximize efficacy and minimize toxicity to improve treatment outcomes for the patients. This article provides an overview of the latest published strategies for clinical and programmatic management of drug-resistant TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.